As you know, NeoStem has undergone positive transformations this past year. The acquisition of Progenitor Cell Therapy (PCT) and Amorcyte furthers our progress in clinical development significantly. We have updated our website to reflect this change with a wealth of information about our own cell therapeutics. We continue to seek...

Earlier today I sent the following letter to our shareholders. Dear NeoStem Shareholders, We would like to take a moment to both look back at 2011 – a transformative year for NeoStem (NYSE Amex: NBS) – and to look ahead to near term catalysts that we expect to move the...

As we continue to take on a leadership role in the development of cell therapies, the commercialization of our products, whether alone or in partnership with large pharmaceutical companies, will be integral to our strategy. We are always looking out for additional leadership to join our team with relevant experience,...